US FDA declines to approve Milestone Pharma's heart rhythm nasal spray
28/03/2025 11:03
March 28 (Reuters) - The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' MIST.O nasal spray to treat a type of heart condition, the company said on Friday. (Reporting by Siddhi Mahatole and Puyaan Singh in Bengaluru; Editing by Shreya Biswas and Maju Samuel) ((siddhi.mahatole@thomsonreuters.com))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview